Sunitinib malate for the treatment of renal cell carcinoma.
about
Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.Impact of imaging measurements on response assessment in glioblastoma clinical trialsVEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.Biomarkers for anti-angiogenic therapy in cancer.Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.Decreased serum level and increased urinary excretion of vascular endothelial growth factor-C in patients with chronic kidney diseaseUNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivoImmune-checkpoint blockade and active immunotherapy for glioma.The potential of sunitinib as a therapy in ovarian cancer.Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.Does angiogenesis play a role in the establishment of mesial temporal lobe epilepsy?Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis.
P2860
Q27329647-925D3191-8FB6-4ED3-958B-3AD5119FB2B7Q33801399-84CEF3E1-7321-47D0-B43B-82DA3BA94CFCQ34331328-805EC8A7-C993-46C6-B0F1-82864439AA8FQ34674541-A91B23E8-2D74-4AD6-9830-EEFC858587FBQ34695003-0EA0A0F1-E7BD-4067-B364-9DB5C29B4AB7Q35002540-F71E0DF2-6EA5-4D1C-8D97-330D2BC576F8Q35079536-D1E793AB-A5C4-4E92-9D8C-BB55BA99492BQ35150788-940232FA-DB21-4734-8AD1-C731C56F8C75Q36465664-4FFEDD07-EFF2-435C-951B-4A5A0791D9E3Q37297144-ACB732A0-BAF4-4B8D-B5BB-77A026CE4F23Q37420586-0BFB4006-F12E-4D67-A5E2-CAE7070B353EQ38144166-03BE11E0-94E9-4BFA-A506-6B32408A4A47Q39064132-80CD5289-2AF8-4F95-AA57-AEEB666EB997Q41505826-57D095FC-C634-4DBE-92C9-680F4EE29AA7Q41895525-9C134E0F-4CBA-448F-ACC1-68CCA116A254Q47358265-86C03239-4D7B-4A6F-BA09-36CC020052F2Q48048760-0CF503CE-A164-4ED9-A666-3CCF5FED3B8AQ55248371-1ECC508A-3E99-4AF3-9A93-0D3A1BBF1427
P2860
Sunitinib malate for the treatment of renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sunitinib malate for the treatment of renal cell carcinoma.
@en
type
label
Sunitinib malate for the treatment of renal cell carcinoma.
@en
prefLabel
Sunitinib malate for the treatment of renal cell carcinoma.
@en
P2860
P1476
Sunitinib malate for the treatment of renal cell carcinoma.
@en
P2093
P2860
P304
P356
10.1517/14656566.2012.689130
P407
P577
2012-06-01T00:00:00Z